FIGURE 4.

Representative neutralizing antibody increase between prime and booster dose by time interval. Participants in phase 1, phase 1/2a, and phase 2 studies aged 18‐55 years and ≥65 years were given a single dose of Ad26.COV2.S (5 × 10¹⁰ vp) at Day 1, followed by a booster dose of the same dose level at 2, 3, or 6 months after the primary dose. Neutralizing antibodies, as measured by wtVNA, were compared before boosting and at 28 days postboost. vp, viral particles; wtVNA, wild‐type virus neutralization assay